Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Anthelminthic Agents

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Report on the 29th annual meeting of the kidney transplantation working group of the German Society of Urology in Marburg 2023].

Urologie (Heidelberg, Germany)·2024

Same author

Time Trends in Causes of Death in People With HIV: Insights From the Swiss HIV Cohort Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024

Same author

DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men-study protocol for a randomized trial.

Trials·2023

Same author

[Imaging in metastatic prostate cancer].

Der Urologe. Ausg. A·2021

Same author

[Minimally invasive surgery for aggressive tumors].

Der Urologe. Ausg. A·2020

Same author

[Algorithms for systemic therapy of prostate cancer, transitional cell carcinoma and renal cell carcinoma].

Der Urologe. Ausg. A·2020

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

[What comes after docetaxel?].

C-H Ohlmann¹, M Stöckle

¹Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Kirrbergerstrasse 1, 66421, Homburg/Saar, Deutschland. Carsten.Ohlmann@uks.eu

Der Urologe. Ausg. A

|November 11, 2009

Summary

Docetaxel is standard first-line treatment for castration-resistant prostate cancer (CRPC). For patients progressing after docetaxel, this review explores current options and promising new treatments like abiraterone acetate and MDV3100.

Area of Science:

Oncology
Urology
Medical Chemistry

Background:

Docetaxel chemotherapy is the standard first-line treatment for castration-resistant prostate cancer (CRPC).
Limited treatment options exist for patients with CRPC who progress after docetaxel therapy.
No established treatment has demonstrated a survival benefit in clinical trials for post-docetaxel CRPC.

Purpose of the Study:

To review available treatment options for patients with progressive castration-resistant prostate cancer (CRPC).
To highlight promising novel therapies currently under clinical investigation for advanced CRPC.
To provide an overview of the treatment landscape for CRPC following docetaxel failure.

Main Methods:

Literature review of clinical trials and treatment guidelines for CRPC.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Jun 18, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

Analysis of data on efficacy and safety of existing and emerging CRPC therapies.

Focus on treatments for patients with documented progression after docetaxel.

Main Results:

Current treatment options for progressive CRPC lack a proven survival benefit.
Abiraterone acetate and MDV3100 are promising agents under investigation.
Further clinical trials are needed to establish new standards of care.

Conclusions:

The management of docetaxel-refractory CRPC remains a significant clinical challenge.
Novel therapeutic agents like abiraterone acetate and MDV3100 show potential for improving outcomes.
Ongoing research is crucial for developing effective treatments for advanced prostate cancer.